CN100334216C - 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 - Google Patents
一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 Download PDFInfo
- Publication number
- CN100334216C CN100334216C CNB200410065733XA CN200410065733A CN100334216C CN 100334216 C CN100334216 C CN 100334216C CN B200410065733X A CNB200410065733X A CN B200410065733XA CN 200410065733 A CN200410065733 A CN 200410065733A CN 100334216 C CN100334216 C CN 100334216C
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- expression
- human endostatin
- endostatin
- molecular chaperones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 6
- 230000014509 gene expression Effects 0.000 claims abstract description 39
- 102000005431 Molecular Chaperones Human genes 0.000 claims abstract description 34
- 108010006519 Molecular Chaperones Proteins 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 108700008165 endostar Proteins 0.000 claims description 32
- 241000894006 Bacteria Species 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 210000003000 inclusion body Anatomy 0.000 abstract description 13
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 108010079505 Endostatins Proteins 0.000 description 25
- 102400001047 Endostatin Human genes 0.000 description 21
- 101500025915 Homo sapiens Angiostatin Proteins 0.000 description 20
- 102400000068 Angiostatin Human genes 0.000 description 18
- 101500026378 Homo sapiens Endostatin Proteins 0.000 description 18
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 17
- 108010058432 Chaperonin 60 Proteins 0.000 description 15
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 241000287828 Gallus gallus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 10
- 101710154918 Trigger factor Proteins 0.000 description 10
- 108010079709 Angiostatins Proteins 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 pGTf2 Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000004862 vasculogenesis Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000004082 Calreticulin Human genes 0.000 description 4
- 108090000549 Calreticulin Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000001043 capillary endothelial cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 238000000407 epitaxy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940049547 paraxin Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031186 Chromogranin-A Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001337451 Polyblastus cancer Species 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 210000000998 shell membrane Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 108010060757 vasostatin Proteins 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410065733XA CN100334216C (zh) | 2004-11-16 | 2004-11-16 | 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410065733XA CN100334216C (zh) | 2004-11-16 | 2004-11-16 | 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1614025A CN1614025A (zh) | 2005-05-11 |
CN100334216C true CN100334216C (zh) | 2007-08-29 |
Family
ID=34764783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410065733XA Active CN100334216C (zh) | 2004-11-16 | 2004-11-16 | 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100334216C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101157729B (zh) | 2007-10-23 | 2011-01-12 | 南京大学 | 一种肿瘤坏死因子相关凋亡配体变体及其应用 |
CN105087725B (zh) * | 2015-08-21 | 2019-04-02 | 江苏大学 | 一种提高大肠杆菌中可溶性重组原动蛋白2β表达水平的方法 |
CN105647847A (zh) * | 2016-03-17 | 2016-06-08 | 南京工业大学 | 产环糊精葡萄糖苷转移酶的基因工程菌及其应用 |
CN106119182B (zh) * | 2016-07-06 | 2019-10-29 | 华中农业大学 | 一种K88黏附素蛋白FaeG的可溶性表达重组菌及其发酵培养方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1236011A (zh) * | 1998-05-15 | 1999-11-24 | 中国科学院上海生物化学研究所 | 一种使用分子伴侣促进蛋白质分泌的方法 |
WO2004096860A1 (ja) * | 2003-04-28 | 2004-11-11 | Sekisui Chemical Co., Ltd. | 目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 |
-
2004
- 2004-11-16 CN CNB200410065733XA patent/CN100334216C/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1236011A (zh) * | 1998-05-15 | 1999-11-24 | 中国科学院上海生物化学研究所 | 一种使用分子伴侣促进蛋白质分泌的方法 |
WO2004096860A1 (ja) * | 2003-04-28 | 2004-11-11 | Sekisui Chemical Co., Ltd. | 目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 |
Also Published As
Publication number | Publication date |
---|---|
CN1614025A (zh) | 2005-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4317181A1 (en) | Recombinant type-i humanized collagen polypeptide, and preparation method therefor and use thereof | |
Lee et al. | Increased production of human granulocyte-macrophage colony stimulating factor (hGM-CSF) by the addition of stabilizing polymer in plant suspension cultures | |
CN100587073C (zh) | 人成纤维细胞生长因子-21的重组表达 | |
CN106282216B (zh) | 一种重组长效鸡干扰素α的制备方法 | |
CN109022464A (zh) | 重组人源型胶原蛋白的羟基化方法 | |
CN110845603A (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
Xu et al. | Expression of soluble, biologically active recombinant human endostatin in Escherichia coli | |
CN102584976B (zh) | 一种人血清淀粉样蛋白a1及其制备方法和应用 | |
CN100334216C (zh) | 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 | |
CN100537765C (zh) | 重组人血管抑素k1-3的制备工艺及其制品在肿瘤治疗药物中的应用 | |
US6316004B1 (en) | Chimeric somatostatin containing protein and encoding DNA, plasmids of expression, method for preparing chimeric protein, strain-producers, immunogenic composition, method for increasing the productivity of farm animals | |
CN106552259A (zh) | 一种融合蛋白及其治疗疾病的用途 | |
CN104418945A (zh) | 一种肽的制备方法及其在制备药物和饲料添加剂中的应用 | |
CN1065875C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN1661019A (zh) | 一种在大肠杆菌中生产重组内皮抑素的方法及其应用 | |
CN1570105A (zh) | 一种人快速收缩骨骼肌肌钙蛋白ⅰ的生产及活性检测方法 | |
CN117510619B (zh) | 一种创新空间结构的重组ⅲ型人源化胶原蛋白微球及其设计、制备工艺和应用 | |
CN104531691A (zh) | 一种获取牛干扰素α的基因的引物、重组牛干扰素α的制备方法 | |
CN100374572C (zh) | 一种体外培养骨骼肌表达体系 | |
CN102321178B (zh) | 一种新的促性腺激素释放激素导向融合蛋白突变体 | |
CN108424459A (zh) | 人血清白蛋白与人突变型肝细胞生长因子的融合蛋白及其制备方法和应用 | |
JPS62501071A (ja) | 成長因子活性を有する新規なポリペプチド及び該ポリペプチドをコ−ドする核酸配列 | |
CN102558330B (zh) | 一种人中期因子抑制肽及其应用 | |
CN1500810A (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN109053897A (zh) | 一种由鸡白细胞介素2、鸡干扰素γ和鸡干扰素α组成的融合蛋白及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHANGZHOU BABIAO BIOPHARMACEUTICAL RESEARCH INSTIT Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20110728 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 213164 CHANGZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110728 Address after: Wujin District of Jiangsu city in Changzhou province 213164 Chang Wu Road No. 801, Science Hall South Building Room 2204 Patentee after: Nanjing University Address before: 210093 Hankou Road, Jiangsu, China, No. 22, No. Patentee before: Nanjing University |
|
C56 | Change in the name or address of the patentee |
Owner name: JIANGSU BABIAO BIOPHARMACEUTICAL RESEARCH INSTITUT Free format text: FORMER NAME: CHANGZHOU BABIAO BIOPHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Wujin District of Jiangsu city in Changzhou province 213164 Chang Wu Road No. 801, Science Hall South Building Room 2204 Patentee after: Jiangsu Target Biomedicine Research Institute Co., Ltd. Address before: Wujin District of Jiangsu city in Changzhou province 213164 Chang Wu Road No. 801, Science Hall South Building Room 2204 Patentee before: Nanjing University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201104 Address after: Room 505, building 05, No. 11, Yaogu Avenue, Jiangbei new district, Nanjing, Jiangsu Province 210000 Patentee after: Nanjing jiruikang Biotechnology Research Institute Co., Ltd Address before: Wujin District of Jiangsu city in Changzhou province 213164 Chang Wu Road No. 801, Science Hall South Building Room 2204 Patentee before: TARGETPHARMA LABORATORIES (JIANDSU) Co.,Ltd. |
|
TR01 | Transfer of patent right |